Cargando…
Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
Autores principales: | La, V., Fujikawa, R., Janzen, D. M., Nunez, M., Bainvoll, L., Hwang, L., Faull, K., Lawson, G., Memarzadeh, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355127/ https://www.ncbi.nlm.nih.gov/pubmed/34376794 http://dx.doi.org/10.1038/s41698-021-00217-9 |
Ejemplares similares
-
RETRACTED ARTICLE: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2017) -
Editorial Expression of Concern: birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2018) -
cIAP1/2 are involved in the radiosensitizing effect of birinapant on NSCLC cell line in vitro
por: Sun, Hao, et al.
Publicado: (2021) -
Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers
por: Singh, Tanya, et al.
Publicado: (2022) -
Retraction Note: An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer
por: Janzen, D. M., et al.
Publicado: (2020)